CytoDyn Secures $30 Million Funding Commitment
CytoDyn Inc. announced a Standby Equity Purchase Agreement with Yorkville Advisors Global, securing a $30 million funding commitment. This agreement allows the company to sell up to $30 million of its common stock over 36 months, providing financial flexibility for its leronlimab program. The arrangement imposes no minimum commitments, enabling CytoDyn to pursue additional financing or partnerships. Proceeds will support working capital and debt repayment. CytoDyn focuses on advancing leronlimab, a monoclonal antibody targeting the CCR5 receptor, aimed at improving patient outcomes in oncology and other diseases.
CytoDyn ( (CYDY) ) has provided an announcement.
On November 3, 2025, CytoDyn Inc. announced a Standby Equity Purchase Agreement with Yorkville Advisors Global, securing a $30 million funding commitment. This agreement allows CytoDyn to sell up to $30 million worth of its common stock to Yorkville over 36 months, providing financial flexibility to further develop its leronlimab program. The arrangement imposes no minimum commitments or restrictions on CytoDyn’s operations, enabling the company to pursue additional financing or strategic partnerships. The proceeds are expected to support working capital and general corporate purposes, including debt repayment.
More about CytoDyn
CytoDyn Inc. is a clinical-stage oncology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor. This receptor is a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. The company is committed to improving patients’ quality of life through therapeutic innovation and aims to bring transformative treatments to patients worldwide.
Average Trading Volume: 1,908,047
Technical Sentiment Signal: Sell
Current Market Cap: $297.3M
